Literature DB >> 34185118

[Management of chemotherapy side effects and their long-term sequelae].

Isabella M Zraik1, Yasmine Heß-Busch2.   

Abstract

Various chemotherapies are used to treat testicular cancer. The most common therapy regimens are BEP (cisplatin, etoposide, bleomycin), carboplatin mono (AUC 7), PEI (cisplatin, etoposide, ifosfamide), TIP (cisplatin, ifosfamide, paclitaxel) and GOP (gemcitabine, oxaliplatin, paclitaxel). This is accompanied by acute and late toxicities. These include general side effects such as anemia, neutropenia, nausea, vomiting, diarrhea, mucositis or paravasation as well as special toxicities like ototoxicity, nephrotoxicity, pulmonary toxicity, neurotoxicity or Raynaud's syndrome. Since young men are usually affected, the possible long-term consequences such as hypogonadism, infertility or the metabolic syndrome are very relevant. Accordingly, adequate management of the possible side effects and long-term consequences in the context of the use of chemotherapy is essential.
© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Anemia; Nausea and vomiting; Quality of life; Testicular cancer; Toxicities

Year:  2021        PMID: 34185118     DOI: 10.1007/s00120-021-01569-7

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  67 in total

1.  Bleomycin and Raynaud's phenomenon.

Authors:  D Adoue; P Arlet
Journal:  Ann Intern Med       Date:  1984-05       Impact factor: 25.391

2.  Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors.

Authors:  Mohammad Abu Zaid; Paul C Dinh; Patrick O Monahan; Chunkit Fung; Omar El-Charif; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair J Beard; Ryan Cook; Sandra Althouse; Shirin Ardeshir-Rouhani-Fard; Howard D Sesso; Robert Huddart; Taisei Mushiroda; Michiaki Kubo; M Eileen Dolan; Lawrence H Einhorn; Sophie D Fossa; Lois B Travis
Journal:  J Natl Compr Canc Netw       Date:  2019-05-01       Impact factor: 11.908

3.  Hypogonadism in testicular cancer patients is associated with risk factors of cardiovascular disease and the metabolic syndrome.

Authors:  C Bogefors; S Isaksson; J Bobjer; M Kitlinski; I Leijonhufvud; K Link; A Giwercman
Journal:  Andrology       Date:  2017-05-23       Impact factor: 3.842

4.  Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid.

Authors:  Matti Aapro; Fred Saad
Journal:  Ther Adv Urol       Date:  2012-04

5.  Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.

Authors:  Michael Auerbach; Peter T Silberstein; R Timothy Webb; Svetlana Averyanova; Tudor-Eliade Ciuleanu; James Shao; Kenneth Bridges
Journal:  Am J Hematol       Date:  2010-09       Impact factor: 10.047

Review 6.  The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis.

Authors:  Ahmed A Alkhateeb; James R Connor
Journal:  Biochim Biophys Acta       Date:  2013-07-25

7.  Effects of high-intensity interval training on fatigue and quality of life in testicular cancer survivors.

Authors:  Scott C Adams; Darren S DeLorey; Margie H Davenport; Adrian S Fairey; Scott North; Kerry S Courneya
Journal:  Br J Cancer       Date:  2018-05-08       Impact factor: 7.640

8.  Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.

Authors:  Marianne Brydøy; Jan Oldenburg; Olbjørn Klepp; Roy M Bremnes; Erik A Wist; Tore Wentzel-Larsen; Erik R Hauge; Olav Dahl; Sophie D Fosså
Journal:  J Natl Cancer Inst       Date:  2009-12-16       Impact factor: 13.506

9.  Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors.

Authors:  H Boer; J H Proost; J Nuver; S Bunskoek; J Q Gietema; B M Geubels; R Altena; N Zwart; S F Oosting; J M Vonk; J D Lefrandt; D R A Uges; C Meijer; E G E de Vries; J A Gietema
Journal:  Ann Oncol       Date:  2015-09-07       Impact factor: 32.976

10.  A randomized double-blind study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention).

Authors:  Mikkel Bandak; Niels Jørgensen; Anders Juul; Jakob Lauritsen; Michael Kreiberg; Peter Sandor Oturai; Jørn Wulff Helge; Gedske Daugaard
Journal:  BMC Cancer       Date:  2017-07-03       Impact factor: 4.430

View more
  8 in total

1.  Morin Inhibits Dox-Induced Vascular Inflammation By Regulating PTEN/AKT/NF-κB Pathway.

Authors:  Jing Yu; Hai-Liang Qi; Hong Zhang; Zi-Yu Zhao; Zi-Yuan Nie
Journal:  Inflammation       Date:  2022-06-15       Impact factor: 4.092

Review 2.  Interaction between gut microbiota and tumour chemotherapy.

Authors:  Le Liu; Yuping Bai; Lin Xiang; Wenbo Qi; Lei Gao; Xiaomei Li; Haiyuan Li; Bofang Wang; Hao Chen
Journal:  Clin Transl Oncol       Date:  2022-09-14       Impact factor: 3.340

Review 3.  Nanomaterial-assisted CRISPR gene-engineering - A hallmark for triple-negative breast cancer therapeutics advancement.

Authors:  Jabeen Farheen; Narayan S Hosmane; Ruibo Zhao; Qingwei Zhao; M Zubair Iqbal; Xiangdong Kong
Journal:  Mater Today Bio       Date:  2022-10-04

Review 4.  Bacteria-Based Synergistic Therapy in the Backdrop of Synthetic Biology.

Authors:  Yawei Bao; Yong Cheng; Wei Liu; Wenguang Luo; Peijie Zhou; Dong Qian
Journal:  Front Oncol       Date:  2022-04-04       Impact factor: 5.738

5.  PLGA-Quercetin Nano-Formulation Inhibits Cancer Progression via Mitochondrial Dependent Caspase-3,7 and Independent FoxO1 Activation with Concomitant PI3K/AKT Suppression.

Authors:  Neera Yadav; Amit Kumar Tripathi; Amna Parveen
Journal:  Pharmaceutics       Date:  2022-06-23       Impact factor: 6.525

6.  Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?

Authors:  Xinye Qian; Wang Hu; Jun Yan
Journal:  Front Immunol       Date:  2022-08-09       Impact factor: 8.786

7.  A Nurse-Led mHealth Self-Management Program (mChemotherapy) for Breast Cancer Patients Undergoing Chemotherapy: Study Protocol of a Randomized Controlled Pilot Study.

Authors:  Nuo Shi; Arkers K C Wong; Frances K Y Wong; Nan Zhang; Xiaobin Lai; Lu Gan
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

8.  Clinical Effect of Fuzheng Guben Decoction in the Treatment of Localized Prostate Cancer and Its Influence on Immune Function under Continuous Nursing Intervention.

Authors:  Yanling Zhou; Lan Liu; Lifei Gao
Journal:  Contrast Media Mol Imaging       Date:  2022-09-16       Impact factor: 3.009

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.